Neurocrine Biosciences, Inc. (NBIX)
| Market Cap | 11.33B |
| Revenue (ttm) | 2.12B |
| Net Income (ttm) | 339.20M |
| Shares Out | 100.98M |
| EPS (ttm) | 3.29 |
| PE Ratio | 34.06 |
| Forward PE | 15.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 548,899 |
| Open | 114.09 |
| Previous Close | 114.00 |
| Day's Range | 111.87 - 114.09 |
| 52-Week Range | 103.63 - 157.98 |
| Beta | 0.36 |
| Analysts | Buy |
| Price Target | 164.09 (+46.3%) |
| Earnings Date | Oct 29, 2024 |
About NBIX
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to trea... [Read more]
Financial Performance
In 2023, Neurocrine Biosciences's revenue was $1.89 billion, an increase of 26.76% compared to the previous year's $1.49 billion. Earnings were $249.70 million, an increase of 61.62%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $164.09, which is an increase of 46.30% from the latest price.
News
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of...
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
SAN DIEGO , Sept. 19, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit at 11:00 a.m.
Neurocrine's experimental drug misses primary goal in schizophrenia trial
Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.
Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia
Second Phase 2 Study for Luvadaxistat Fails to Meet Primary Endpoint as Potential Treatment for Cognitive Impairment Associated with Schizophrenia Results Confounded by Variability in Cognition Measur...
Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference
SAN DIEGO , Sept. 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the 2024 Cantor Global Healthcare Conference in New York at 3:05 p.m.
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$3...
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Wednesday, Neurocrine Biosciences, Inc. (NASDAQ: NBIX) topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Despite Neurocrine Biosciences, Inc. muscarinic receptor drug NBI-'568 not surpassing competitors in Schizophrenia, several other drugs of the same type are being developed for large market indication...
Neurocrine Biosciences to Participate at Investor Conferences in September
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York 2024 Wells Fargo Healthcare Conference on September 5 in Boston SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Neurocrine ...
Neurocrine Biosciences: Disappointing Data From A Key Readout Hits The Stock Hard
Neurocrine Biosciences posted disappointing Phase II data for its schizophrenia drug NBI-1117568, driving a steep fall in the share price. NBI-568 came up short in terms of PANSS reduction, with a 7.5...
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
Tokyo, Japan and Cambridge, UK, 28 August 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner N...
Neurocrine's schizophrenia drug meets main goal in mid-stage study
Neurocrine Biosciences said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
The Once-Daily 20 mg Dose Met the Primary Endpoint, Demonstrating a Statistically Significant 7.5-Point Improvement (p=0.011, 0.61 Effect Size) in the PANSS Total Score Compared to Placebo at Week 6 w...
Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
SAN DIEGO , Aug. 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Canaccord Genuity 44th Annual Growth Conference in Boston at 3:30 p.m. Eastern Time on Wednesda...
Neurocrine Biosciences Delivering Strong Core Results, And Significant Pipeline Value Could Be On The Way
Ingrezza sales are on the rise, with a 32% increase in sales in Q2'24, and there is still an attractive runway of growth ahead for the drug. The Phase II results of '845 in major depressive disorder e...
Neurocrine Biosciences, Inc. (NBIX) Q2 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich -...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
INGREZZA® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ® (valbenazine) 2024 Net Product Sales Guidance Raised to $2.25 - $2.3 Billion ...
Neurocrine's Growing Sales, Profits Attracting Big Money
Sales and profits have been rocketing upwards for Neurocrine Biosciences, Inc. (NBIX), and a recent regulatory approval should continue that trend.
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed ve...
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Thursday, August 1 SAN DIEGO , July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quar...
Neurocrine Biosciences: Diverse Pipeline, High Margins, And Growth Potential In Biotech
Neurocrine Biosciences develops treatments for neurological, neuroendocrine, and neuropsychiatric conditions with leading products Ingrezza and Orilissa. NBIX's diverse pipeline includes promising can...
Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Ingrezza Sprinkle, granules, has been recently granted with the FDA approval. Supporting $2.1-2.2 billion in 2024 sales for the whole Ingrezza franchise guided by Neurocrine's management. Neurocrine B...
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
PDUFA Target Action Dates in Late December 2024 Highly Selective CRF1 Antagonist is the Potential First New Treatment for CAH in 70 Years SAN DIEGO , July 1, 2024 /PRNewswire/ -- Neurocrine Bioscience...
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at t...